In the United States, routine recommendations for infant hepatitis B vaccination have served as a cornerstone of public health policy for more than three decades. First introduced for all infants in 1991, the immunization strategy was later refined to specify that the initial dose should be administered within 24 hours of birth. This proactive measure drastically cut infection rates by protecting newborns from vertical transmission—passing the virus from mother to child during birth—as well as early childhood exposure. However, a major shift in federal guidance enacted in December 2025 by the U.S. Centers for Disease Control and Prevention (CDC) under the Trump Administration has altered this landscape, sparking intense debate among infectious disease experts, pediatricians, and public health officials.

Under the updated federal guidelines, the universal recommendation to administer the hepatitis B vaccine at birth has been rescinded for babies born to mothers who test negative for the virus. Instead of a blanket recommendation, the CDC now advises a shared decision-making model. This approach places the responsibility on parents and clinicians to determine what is medically appropriate on a case-by-case basis. Families can now opt for a dose shortly after birth or choose to delay the first vaccination until the infant is at least two months old. For newborns whose mothers test positive for hepatitis B, or whose screening status remains unknown, the federal agency maintains its previous stance, continuing to recommend a protective dose shortly after delivery.

The policy pivot has immediately drawn scrutiny from medical professional societies and state health departments concerned about the potential resurgence of a preventable disease. To measure the real-world implications of this policy change, a new study published today in the Annals of Internal Medicine employs sophisticated computer modeling to simulate the hepatitis B infection status of an entire birth cohort in the United States. Researchers tracked a simulated population of infants born over a single year, following their health outcomes over the first two decades of life under the new recommendations. The findings paint a stark picture: if the shared decision-making model leads to an estimated vaccination uptake of only 26% at birth, chronic hepatitis B cases nationwide could surge by a dramatic 225%.

When Should Kids Get the First Dose of Hepatitis B Vaccine?

The question of timing has become a central flashpoint in contemporary public health debates, pitting federal policy shifts against decades of established clinical consensus.

"It’s been challenged in many states and by professional societies, but we wanted to add some evidence to the conversation about what the potential impact of those changes could be," says Dr. Amir Mohareb, an infectious-disease researcher at Harvard Medical School and Massachusetts General Hospital, and one of the principal authors of the new study.

To evaluate these impacts, the research team constructed a computer simulation model designed to project outcomes for approximately 3.6 million children born in the United States in a single calendar year. The model compared multiple scenarios to determine how many children would contract hepatitis B under different vaccination timelines. These scenarios included the continuation of historical CDC recommendations, situations where the initial birth dose was delayed by two months, and outcomes reflecting the newly implemented shared decision-making model where birth doses drop significantly.

The mathematical modeling yields concerning projections for pediatric health outcomes. According to the simulation, if the administration of the first hepatitis B vaccine dose is delayed until an infant reaches two months of age—and overall uptake drops to 75%—the nation would still experience a 19% increase in chronic hepatitis B cases compared to a baseline where every child receives the vaccine at birth. However, as the acceptance rate for the early dose plummets under the shared decision-making framework, the consequences compound rapidly. When the early vaccination rate drops to the modeled 26% projection, the increase in chronic infections skyrockets to 225%.

Dr. Mohareb emphasizes that these figures represent the fallout from just a single year of births. The cumulative effect of relaxed vaccination schedules over successive generations could introduce severe long-term public health burdens.

"Imagine that happening year after year after year after year," Mohareb notes, underscoring the compounding nature of infectious disease risks. "That could quickly become thousands and thousands of new infections, and even a small number of new infections could result in lifelong chronic infection that could be detrimental to families, lead to more cases of cancer, and [become] costly to the health care system."

Chronic hepatitis B is a serious viral infection that attacks the liver. While adults who contract the virus often clear it naturally, infants and young children who are infected face a dramatically higher risk of developing chronic, lifelong infections. Chronic hepatitis B can silently damage the liver over decades, frequently leading to severe complications such as cirrhosis, liver failure, and hepatocellular carcinoma, a primary form of liver cancer. Because early childhood infections carry the highest risk of chronicity, public health frameworks have historically prioritized the birth dose as an essential immunological safety net.

The researchers behind the new study point out that the medical community does not need to reinvent the wheel to understand the efficacy of the original guidelines. Decades of robust clinical research and real-world implementation have already validated the safety and success of the universal birth dose strategy.

"All three of these studies complement each other, in a good way, and provide some modicum of evidence so that we don’t need to risk doing a clinical trial or testing this on people," Mohareb says, reflecting on the broader body of literature surrounding the policy change. "We have those experiments. Decades ago, clinical trials already proved the efficacy of the existing approach, so that we would have the benefit now of advancing medical progress and not needing to reopen that question."

As state health departments, pediatric associations, and individual family practitioners grapple with how to interpret the CDC’s updated guidance, studies like the one published in the Annals of Internal Medicine provide empirical data to inform ongoing clinical discussions. With millions of newborns entering the healthcare system under the new shared decision-making framework, public health experts continue to monitor vaccination rates closely to determine whether the projected rise in chronic infections will materialize in the years ahead.